Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RuXoCoil: Ruxolitinib for treatment of COVID-19-induced lung injury ARDS
2020-001732-10Phase 2Completed
- Sponsor
- Philipps-Universität Marburg
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ruxolitinib in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by Philipps-Universität Marburg. Primary endpoint: Overall survival at 28 days. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001732-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001732-10.